![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer...
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSideā¢ with Plus...
Biocept, Inc. (Nasdaq: BIOC) (āBioceptā or the āCompanyā), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C...
Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer...
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a...
Biocept, Inc. (Nasdaq: BIOC) (āBioceptā or the āCompanyā), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was...
Biocept, Inc. (Nasdaq: BIOC) (āBioceptā or the āCompanyā) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 3 | 3 | 3 | 16 | 3 | CS |
26 | 0 | 0 | 3 | 3 | 3 | 16 | 3 | CS |
52 | 0 | 0 | 3 | 3.1 | 0.0228 | 315 | 2.52008112 | CS |
156 | 2 | 200 | 1 | 3.1 | 0.0126 | 257 | 2.17634098 | CS |
260 | 2 | 200 | 1 | 3.1 | 0.0126 | 257 | 2.17634098 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions